仅需毫米规格的人工培育类脑组织，机器人就可实现自主决策、行进避障。"生物中枢＋机械控 制"这一颇具未来感的场景，已在天津大学实验室内成为现实。 这个片上脑机接口智能交互系统，由脑机交互与人机共融海河实验室团队牵头、南方科技大学等团 队协作开发，能够通过细胞驱动实现"意念控制"。天津大学医学院教授李晓红说，目前团队正聚焦技术 的优化和落地应用。 距实验室仅一公里外，合源生物科技股份有限公司的研发基地里，缓慢晃动的生物反应器中孕育着 血液肿瘤患者生的希望。 作为一家聚焦于细胞治疗的企业，合源生物成立7年多来，已有两项细胞治疗国产CAR－T药物适 应症获批上市。合源生物创始人、CEO吕璐璐对未来信心满满："新的一年，企业将在产能扩增、推进 全球布局等方面深耕。" 近年来，天津加速布局未来产业，在合成生物、脑机接口等特色领域不断发力，已获批组建29家全 国重点实验室，建设细胞生态、先进计算与关键软件等7家海河实验室，国家和部级创新平台总数近280 家。如今，在智算芯片、细胞与基因治疗等关键技术领域，天津不断实现新突破。 不仅如此，天津科教资源丰富，聚力打造的天开高教科创园加快科技成果转化、科技企业孵化，累 计注册企业 ...

（来源：天津日报） 转自：天津日报 岁序更替，津沽大地万象更新。作为北方经济重镇和国家先进制造研发基地，天津因地制宜发展新质生 产力，正加速布局培育未来产业、发展壮大新兴产业、巩固提升传统产业，面向"十五五"努力开好局、 起好步，不断激发经济发展新动能、新活力。 不仅如此，天津科教资源丰富，聚力打造的天开高教科创园加快科技成果转化、科技企业孵化，累计注 册企业超4500家。 "天津将抢抓北京（京津冀）国际科技创新中心建设扩围机遇，聚焦科技创新和产业创新深度融合，强 化破题意识、系统推进，谋深抓实一批改革举措、重大项目和创新任务，为'十五五'谋好篇、开好 局。"天津市科技局局长崔振平说。 打造新集群 新兴产业积蓄新动能 瞄准新赛道 未来产业实现新突破 仅需毫米规格的人工培育类脑组织，机器人就可实现自主决策、行进避障。"生物中枢+机械控制"这一 颇具未来感的场景，已在天津大学实验室内成为现实。 这个片上脑机接口智能交互系统，由脑机交互与人机共融海河实验室团队牵头、南方科技大学等团队协 作开发，能够通过细胞驱动实现"意念控制"。天津大学医学院教授李晓红说，目前团队正聚焦技术的优 化和落地应用。 距实验室仅一公里外， ...

岁序更替，津沽大地万象更新。作为北方经济重镇和国家先进制造研发基地，天津因地制宜发展新质生 产力，正加速布局培育未来产业、发展壮大新兴产业、巩固提升传统产业，面向"十五五"努力开好局、 起好步，不断激发经济发展新动能、新活力。 瞄准新赛道，未来产业实现新突破 仅需毫米规格的人工培育类脑组织，机器人就可实现自主决策、行进避障。"生物中枢+机械控制"这一 颇具未来感的场景，已在天津大学实验室内成为现实。 这个片上脑机接口智能交互系统，由脑机交互与人机共融海河实验室团队牵头、南方科技大学等团队协 作开发，能够通过细胞驱动实现"意念控制"。天津大学医学院教授李晓红说，目前团队正聚焦技术的优 化和落地应用。 距实验室仅一公里外，合源生物科技股份有限公司的研发基地里，缓慢晃动的生物反应器中孕育着血液 肿瘤患者生的希望。 作为一家聚焦于细胞治疗的企业，合源生物成立7年多来，已有两项细胞治疗国产CAR-T药物适应症获 批上市。合源生物创始人、CEO吕璐璐对未来信心满满："新的一年，企业将在产能扩增、推进全球布 局等方面深耕。" 近年来，天津加速布局未来产业，在合成生物、脑机接口等特色领域不断发力，已获批组建29家全国重 点实 ...

血霁生物的创始人朱芳芳表示：感谢本轮投资人对于血霁生物的投资，这笔资金将支持我们全力奔赴药 物研发的终点和公司成长的重要节点。血霁生物产品的稀缺性、稳步的发展战略和健康的财务状态，为 投资人本轮增资提供了足够的信心。虽然新领域新药物的研发和拓荒充满荆棘与挑战，但自身的技术突 破和外部的产业生态带给我们足够的底气与勇气，让我们"再造热血，'霁'续生命"。 投资界12月26日消息，近日，苏州血霁生物科技有限公司（以下简称"血霁生物"）宣布 完成过亿元人 民币的B1轮股权融资，并获得多家银行过亿元人民币的基于授信的债权融资，用于发展血霁生物的核 心业务血小板世系的体外再生，以解决血源供应短缺和血液传播疾病等问题，并大大减少输血带来的不 良后果，以及开发围绕再生的血小板衍生而来的新型药物。本轮B1轮股权融资首关由海南大健康医学 集团领投，永徽创投等跟投，融资金额超亿元人民币。本轮资金将重点用于血霁生物前两条管线的临床 试验和其余重点管线的临床前工作，用于支持血霁生物的快速成长。 同时血霁生物获得1.2亿元人民币的银行授信，成为公司发展的储备金：招商银行股份有限公司苏州分 行、宁波银行股份有限公司江苏自贸试验区苏州片区 ...

开能健康（300272.SZ）12月24日在投资者互动平台表示，公司对细胞行业的前景持积极态度，并早在 2014年开始已在该领域进行了深入布局，创立了原能细胞科技集团。根据公司公告，干细胞治疗作为细 胞治疗的一个重要分支，近年来得到了国家政策的支持，公司紧跟政策导向，积极布局细胞业务板块。 公司通过收购原能集团部分子公司股权，获得了包括张江核心地段的土地、细胞行业专利授 权、"YT001注射液"临床试验批件等在内的一系列资产和项目，进一步完善了公司在细胞治疗领域的产 业链。 公司在干细胞治疗领域的布局具体包括：1、细胞制剂制备业务：公司依托成熟的干细胞与免疫 细胞制备工艺，承接市场需求，包括药企细胞治疗药物的规模化代工生产、科研机构临床研究用细胞定 制服务等。2、细胞试剂业务：公司掌握了细胞制备工艺全链条的自主技术储备，成功研发出拥有自主 知识产权的细胞制备制剂产品，通过技术输出成为产业链关键供应商。3、细胞技术产品研发业务：公 司自主研发的"YT001注射液"已获批准开展I/IIa期临床试验，未来将通过技术产品上市、技术转让或收 益分成实现商业化；4、宠物保健抗衰领域，利用干细胞疗法、NK细胞、外泌体及NM ...

Core Viewpoint - Company Jindalai is making a significant shift into the health sector by investing over 310 million yuan in two companies, marking its transition from environmental protection to a dual focus on "environment + health" [2] Investment Details - Jindalai announced an investment of 280 million yuan to acquire a 34% stake in Jici Medical, focusing on cell therapy, and an additional 30 million yuan for a 10% stake in Zhongke Hongtai, which specializes in medical robotics [2][6] - The investment in Jici Medical positions Jindalai as the second-largest shareholder, just behind the controlling shareholder [3] Financial Performance of Target Companies - Jici Medical reported revenues of 11.23 million yuan and a net profit of 1.15 million yuan for the first three quarters of 2025, but its equity remains negative at -3.15 million yuan [4] - Zhongke Hongtai's revenue for the same period was only 102,600 yuan, with a net loss of 550,770 yuan, indicating ongoing financial challenges [6] Strategic Alignment with National Policies - Both investments align with national strategic emerging industries, with Jici Medical focusing on cell therapy and Zhongke Hongtai on the trend of intelligent medical devices [6] - The "14th Five-Year Plan" identifies biomanufacturing as a new economic growth point, with stem cell technology included as a key area [6] Challenges in Core Business - Jindalai's core environmental business is under pressure, with a revenue decline of 23.5% year-on-year for the first three quarters of 2025, leading to a search for new growth avenues [8] - The company is facing a "collection battle" with multiple lawsuits, indicating difficulties in cash flow management [9][12] Cash Flow and Investment Risks - Despite current cash flow stability, with over 2.2 billion yuan in liquid assets, future investments in the new sectors may strain resources, especially given the financial status of the target companies [14] - The high-risk nature of clinical trials in cell therapy and the complex registration processes for medical robots pose additional uncertainties for Jindalai's new ventures [14][15] Technical Synergy Concerns - There is limited technical synergy between Jindalai's core wastewater treatment technology and the new health sector investments, which may hinder the company's ability to leverage its existing expertise [15]

中原生物医药产业的下一片蓝海在哪里？答案或许就藏在"细胞"之中。近日，2025年度第二批河南省重 大产业关键技术攻关"揭榜挂帅"项目——"细胞治疗关键技术与新药创制"启动，一场瞄准细胞治疗核心 技术的"创新战役"在河南省科学院正式打响。 启动活动上，项目负责人、省科学院生物医学研究所任务科学家王盛典研究员对项目整体实施方案作了 详细介绍。中国科学院院士陈润生对项目的前瞻性布局、创新思路及实施方案给予高度评价，同时建 议，团队应积极运用人工智能等新兴技术推动研究范式变革，加强跨领域、跨机构合作，凝聚创新合 力，并始终坚持以临床需求为导向，力争产出能够切实解决重大疾病问题的标志性成果。其他与会专家 就具体实施路径与协同推进机制进行了深入研讨，并提出具体意见建议。 该项目的启动实施，不仅是一次科研攻关的起跑信号，更是一次全链条协同作战的深度动员。河南正 以"揭榜挂帅"机制为引擎，全力突破生物医药关键技术瓶颈、推动生物医药产业突围升级，为我省培育 新质生产力和高质量发展注入全新动能。（记者 师喆） 责任编辑： 郭栩汝 随着"细胞治疗关键技术与新药创制"项目正式揭榜，来自产学研各界的领军人物齐聚中原，如同挂帅出 征的攻 ...

Core Insights - The future business environment in 2026 will be shaped by a combination of global dynamics, technological advancements, policy regulations, and societal expectations, emphasizing the importance of human connections in business [1][3][12] Group 1: Economic Climate - The global economy is on a path of moderate recovery, undergoing structural reorganization influenced by central bank monetary policies and geopolitical factors, which will affect capital costs and corporate financing [1][2] - China is focusing on "high-quality development," with 2026 marking a harvest period for the 14th Five-Year Plan and a sowing period for the 15th, emphasizing innovation, supply chain resilience, data security, and financial stability [2] Group 2: Technological Revolution - Technological breakthroughs are transitioning from being influencing factors to decisive variables, with AI becoming integral across industries, and advancements in energy systems and life sciences accelerating commercialization [3][8] - The emergence of new roles such as AI caretakers and ethical guardians will enhance the relationship between humans and technology, fostering a warmer and more trustworthy interaction [8][10] Group 3: Competitive Landscape - The market is finding a new balance between clear regulatory frameworks and the normalization of cross-industry integration, leading to a more transparent and fair competitive environment [5][10] - Consumers are evolving into discerning decision-makers who value emotional connections with brands, prompting companies to shift from mere product providers to experience creators [7][10] Group 4: Organizational Health - Companies must invest in their workforce, focusing on skill enhancement and fostering a sense of purpose and trust, which are essential for organizational resilience and adaptability [11][12] - A healthy organization is characterized by agile connections, intelligent redundancy, and a strong value system that guides its direction amidst change [11][12] Group 5: Business Essence - The essence of business in 2026 will revolve around creating genuine value for customers, providing growth opportunities for employees, and ensuring sustainable practices for society [12][13] - Companies are encouraged to embrace complexity with humility and openness, building a solid foundation for sustainable development through resilient coexistence and meaningful innovation [13]

Core Insights - The core competitive advantage of companies in the biopharmaceutical industry has shifted from singular technological breakthroughs to the ability to accurately predict frontier trends, diversify pipeline layouts, and construct an innovative ecosystem across the entire industry chain [1][3]. Company Overview - Boya Life has been recognized for its significant breakthroughs in the field of cells and exosomes, earning multiple awards in 2025, including the "Top 100 in China's Medical Health Industry Chain Service" and "Best Biotech Innovation Product Award" [1]. - Boya Life has been deeply engaged in cell technology for 16 years, operating under three brands: Boya Stem Cells, Boya Medical, and Boya Pharmaceutical, covering cell storage and health management, automated medical devices, and drug and medical technology research and development [3]. Industry Trends - Cell therapy, represented by life sciences, is viewed as a strategic, leading, disruptive, and forward-looking emerging industry, essential for driving technological progress and industrial upgrades in China [3]. - Exosomes, as key mediators of intercellular communication, have unique properties that make them suitable for applications in anti-aging, chronic disease intervention, and health maintenance [3]. Product Development - Boya Life has a robust pipeline in cell therapy, with nearly 20 cell medical technology and drug development projects underway, addressing major diseases in orthopedics, gynecology, and autoimmune systems, while also exploring anti-aging solutions [3][4]. - In the "Exosome+" sector, Boya provides GMP-grade stem cell exosome raw materials and commercial services, achieving positive progress in skin repair, inflammation repair, and degenerative diseases of the brain and eyes [4]. Market Position - Boya Stem Cells holds a 32% market share in China's placental mesenchymal stem cells, having provided cell storage and health management services to over 150,000 families [4]. - Boya Life leads the domestic cell industry in high-quality standards and standardization, certified by international organizations such as AABB and WHO [4]. Future Outlook - The company aims to continue driving the development of new productive forces represented by cell technology through ongoing innovation in technology research and product service models, contributing to public health improvement and the advancement of modern medicine [5].

Core Insights - The construction of the largest specialized cell therapy laboratory in Southwest China is entering a critical phase, with a total investment of 130 million yuan and an area of approximately 6,000 square meters, set to be completed by July next year [1][5]. Group 1: Laboratory Development - The laboratory is being built according to GMP standards and will serve as a crucial infrastructure for the cell therapy field in Southwest China, supporting the full chain development from laboratory to commercialization [3][5]. - The project is a key component of the national "two重" project, receiving significant policy support, including funding from the National Development and Reform Commission [5][6]. - The design of the laboratory allows for flexible expansion, catering to the needs of future resident companies, which will lower the research and development barriers for startups [5][6]. Group 2: Industry Ecosystem - The cell therapy industry in Chengdu is rapidly forming an innovative ecosystem, bolstered by strong local medical resources and government support [6]. - The project has benefited from comprehensive policy support, including land assurance, financial assistance, and talent cultivation [6]. - The park is attracting various companies in the cell and gene therapy sectors, fostering collaboration in technology research, clinical applications, and industrialization [6].